Skip to main content
SpringerLink
Log in

Fingolimod will capture the largest market share of all emerging multiple sclerosis (MS) therapies in 2017,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017. Media Release: 29 May 2008. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fingolimod will capture the largest market share of all emerging multiple sclerosis (MS) therapies in 2017,. Pharmacoecon. Outcomes News 555, 10 (2008). https://doi.org/10.2165/00151234-200805550-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805550-00023

Keywords

Search

Navigation